Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1945 4
1946 5
1947 5
1948 4
1949 1
1950 2
1951 3
1952 2
1953 3
1954 4
1958 2
1960 1
1961 1
1962 3
1963 2
1964 2
1965 2
1968 1
1969 5
1970 13
1971 58
1972 146
1973 234
1974 217
1975 171
1976 219
1977 214
1978 217
1979 166
1980 187
1981 185
1982 137
1983 145
1984 146
1985 132
1986 126
1987 147
1988 119
1989 115
1990 146
1991 177
1992 123
1993 146
1994 136
1995 215
1996 198
1997 244
1998 341
1999 335
2000 379
2001 442
2002 518
2003 578
2004 671
2005 913
2006 1003
2007 1168
2008 1348
2009 1229
2010 1372
2011 1416
2012 1498
2013 1401
2014 1523
2015 1558
2016 1748
2017 1724
2018 1791
2019 1893
2020 897
Text availability
Article attribute
Article type
Publication date

Search Results

27,022 results
Results by year
Filters applied: . Clear all
Page 1
Medical Use of Cannabinoids.
Fraguas-Sánchez AI, Torres-Suárez AI. Fraguas-Sánchez AI, et al. Drugs. 2018 Nov;78(16):1665-1703. doi: 10.1007/s40265-018-0996-1. Drugs. 2018. PMID: 30374797 Review.
Cannabinoid receptors, endocannabinoids and the enzymes responsible for their biosynthesis and degradation constitute the endocannabinoid system. ...Considering the importance of the endocannabinoid system and the therapeutic potential of cannabinoids in this vast n …
Cannabinoid receptors, endocannabinoids and the enzymes responsible for their biosynthesis and degradation constitute the endocannabi …
Cannabinoids: from pot to lab.
Papaseit E, Pérez-Mañá C, Pérez-Acevedo AP, Hladun O, Torres-Moreno MC, Muga R, Torrens M, Farré M. Papaseit E, et al. Int J Med Sci. 2018 Aug 6;15(12):1286-1295. doi: 10.7150/ijms.27087. eCollection 2018. Int J Med Sci. 2018. PMID: 30275754 Free PMC article. Review.
In recent years, the line between the natural (cannabis) and the synthetic (synthetic cannabinoids), the recreational (cannabis) and the medical (pharmaceutical cannabinoids and medical cannabis) has been crossed. ...We have also analyzed serious adverse reactions a …
In recent years, the line between the natural (cannabis) and the synthetic (synthetic cannabinoids), the recreational (cannabis) and …
Pharmacogenetics of Cannabinoids.
Hryhorowicz S, Walczak M, Zakerska-Banaszak O, Słomski R, Skrzypczak-Zielińska M. Hryhorowicz S, et al. Eur J Drug Metab Pharmacokinet. 2018 Feb;43(1):1-12. doi: 10.1007/s13318-017-0416-z. Eur J Drug Metab Pharmacokinet. 2018. PMID: 28534260 Free PMC article. Review.
Although the application of medical marijuana and cannabinoid drugs is controversial, it is a part of modern-day medicine. The list of diseases in which cannabinoids are promoted as a treatment is constantly expanding. ...This review organizes the current knowledge …
Although the application of medical marijuana and cannabinoid drugs is controversial, it is a part of modern-day medicine. The list o …
The pharmacokinetics and the pharmacodynamics of cannabinoids.
Lucas CJ, Galettis P, Schneider J. Lucas CJ, et al. Br J Clin Pharmacol. 2018 Nov;84(11):2477-2482. doi: 10.1111/bcp.13710. Epub 2018 Aug 7. Br J Clin Pharmacol. 2018. PMID: 30001569 Free PMC article. Review.
There is increasing interest in the use of cannabinoids for disease and symptom management, but limited information available regarding their pharmacokinetics and pharmacodynamics to guide prescribers. ...The pharmacokinetics of cannabinoids and the effects observed …
There is increasing interest in the use of cannabinoids for disease and symptom management, but limited information available regardi …
Cannabinoids for Treatment of MS Symptoms: State of the Evidence.
Rice J, Cameron M. Rice J, et al. Curr Neurol Neurosci Rep. 2018 Jun 19;18(8):50. doi: 10.1007/s11910-018-0859-x. Curr Neurol Neurosci Rep. 2018. PMID: 29923025 Review.
This paper provides an overview of the available cannabinoid-based formulations, a summary of the highest quality evidence for the use of cannabinoids for treating spasticity and pain associated with multiple sclerosis (MS), and a discussion of possible dosing regim …
This paper provides an overview of the available cannabinoid-based formulations, a summary of the highest quality evidence for the us …
Pharmacology of cannabinoids in the treatment of epilepsy.
Gaston TE, Friedman D. Gaston TE, et al. Epilepsy Behav. 2017 May;70(Pt B):313-318. doi: 10.1016/j.yebeh.2016.11.016. Epub 2017 Jan 10. Epilepsy Behav. 2017. PMID: 28087250 Review.
Cannabinoids as a whole are very lipophilic, resulting in decreased bioavailability, which presents challenges in optimal drug delivery. ...This article is part of a Special Issue titled Cannabinoids and Epilepsy....
Cannabinoids as a whole are very lipophilic, resulting in decreased bioavailability, which presents challenges in optimal drug delive …
Cannabinoids: Medical implications.
Schrot RJ, Hubbard JR. Schrot RJ, et al. Ann Med. 2016;48(3):128-41. doi: 10.3109/07853890.2016.1145794. Epub 2016 Feb 25. Ann Med. 2016. PMID: 26912385 Review.
While herbal cannabis has not met rigorous FDA standards for medical approval, specific well-characterized cannabinoids have met those standards. ...Novel ways to manipulate the endocannbinoid system are being explored to maximize benefits of cannabinoid therapy and …
While herbal cannabis has not met rigorous FDA standards for medical approval, specific well-characterized cannabinoids have met thos …
Cannabinoids for Symptom Management and Cancer Therapy: The Evidence.
Davis MP. Davis MP. J Natl Compr Canc Netw. 2016 Jul;14(7):915-22. doi: 10.6004/jnccn.2016.0094. J Natl Compr Canc Netw. 2016. PMID: 27407130 Review.
Cannabinoids are known to modulate a multitude of monoamine receptors. Structurally, there are 3 groups of cannabinoids. Multiple studies, most of which are of moderate to low quality, demonstrate that tetrahydrocannabinol (THC) and oromucosal cannabinoid com …
Cannabinoids are known to modulate a multitude of monoamine receptors. Structurally, there are 3 groups of cannabinoids. Multi …
Pharmacokinetics and pharmacodynamics of cannabinoids.
Grotenhermen F. Grotenhermen F. Clin Pharmacokinet. 2003;42(4):327-60. doi: 10.2165/00003088-200342040-00003. Clin Pharmacokinet. 2003. PMID: 12648025 Review.
However, its acid metabolite THC-COOH, the non-psychotropic cannabidiol (CBD), several cannabinoid analogues and newly discovered modulators of the endogenous cannabinoid system are also promising candidates for clinical research and therapeutic uses. Cannabinoid …
However, its acid metabolite THC-COOH, the non-psychotropic cannabidiol (CBD), several cannabinoid analogues and newly discovered mod …
Cannabinoids as Anticancer Drugs.
Ramer R, Hinz B. Ramer R, et al. Adv Pharmacol. 2017;80:397-436. doi: 10.1016/bs.apha.2017.04.002. Epub 2017 Jun 12. Adv Pharmacol. 2017. PMID: 28826542 Review.
So far experience with anticarcinogenic effects of cannabinoids is confined to in vitro studies and animal models. Although a bench-to-bedside conversion remains to be established, the current knowledge suggests cannabinoid compounds to serve as a group of drugs tha …
So far experience with anticarcinogenic effects of cannabinoids is confined to in vitro studies and animal models. Although a bench-t …
27,022 results
Jump to page

Searches related to "cannabinoids"

Feedback